with regard to the preparation of compounds a and b reference is made expressly to wo 00 / 08014 . the inhibiting effect of the two substances on blood clotting was measured by determining the prolongation of aptt ( activated partial thromboplastin time ) as follows : the aptt was determined using a biomatic — b 10 coagulometer made by messrs desaga ( wiesloch ). the test substance was placed in the test tubes prescribed by the manufacturer with 0 . 1 ml of human citrated plasma and 0 . 1 ml of ptt reagent . the preparations were incubated for three minutes at 37 ° c . the clotting reaction was started by the addition of 0 . 1 ml of calcium solution . the time taken for the plasma to clot was measured by the apparatus as the calcium solution was added . analogous test preparations to which 0 . 1 ml of diethyl barbiturate acetate buffer had been added were used as controls . according to the definition of ec 200 , the substance concentration at which the aptt time was double that of the control was determined using a dosage - activity curve . the inhibiting effect on the human fibrinogen receptor ( glycoprotein iib / iiia ) was investigated as follows : a suspension of human thrombocytes was incubated with 3 h - bibu 52 [=( 3s , 5s )- 5 -[( 4 ′- amidino - 4 - biphenylyl ) oxymethyl ]- 3 -[( carboxy ) methyl ]- 2 - pyrrolidinone [ 3 - 3 h - 4 - biphenylyl ]], which replaces the ligand 125 i - fibrinogen known from the literature ( cf . de - a - 4 214 245 ), and various concentrations of the substance being tested . the free and bound ligands were separated by centrifugation and quantitatively determined by scintillation counting . the inhibition of the 3 h - bibu 52 binding by the test substance was determined from the measurements obtained . to do this , donor blood was taken from an anticubital vein and anticoagulated with trisodium citrate ( final concentration : 13 mm ). the blood was centrifuged for ten minutes at 170 × g and the supernatant platelet - rich plasma ( prp ) was removed . the remaining blood was sharply centrifuged once more to obtain plasma . the prp was diluted 1 : 10 with autologous plasma . 750 μl thereof were incubated with 50 μl of physiological saline solution , 100 μl of test substance solution , 50 μl of 14 c - sucrose ( 3 , 700 bq ) and 50 μl of 3 h - bibu 52 ( final concentration : 5 nm ) at ambient temperature for 20 minutes . in order to measure the non - specific binding , 5 μl of bibu 52 ( final concentration : 30 μm ) were used instead of the test substance . the samples were centrifuged for 20 seconds at 10000 × g and the supernatant was removed . 100 μl thereof were assayed in order to quantify the free ligand . the pellet was dissolved in 500 μl of 0 . 2n naoh , 450 μl were mixed with 2 ml of scintillator and 25 μl of 5n hcl and assayed . the residual plasma still remaining in the pellet was determined from the 14 c content while the bound ligand was determined from the 3 h measurement . after subtraction of the non - specific binding the pellet activity was plotted against the concentration of test substance and the concentration which produced a 50 % inhibition of binding ( ic 50 ) was determined . aptt inhibition of fibrinogen ( ec 200 in receptor substance μmol / l ) ( ic 50 in μmol / l ) a 0 . 013 0 . 006 b 0 . 026 0 . 049 in view of their pharmacological properties these two active substances a and b and the physiologically acceptable salts thereof are particularly suitable for preventing and treating arterial thrombotic diseases , such as for example preventing coronary thrombosis , preventing the occlusion of shunts or stents , preventing reocclusions after bypass operations or angioplasty and for antithrombotic support ( preventing the reocclusion of coronary arteries ) during and after thrombolytic treatment , such as e . g . the present invention thus relates to a method of treating and preventing arterial thrombotic diseases , particularly the abovementioned arterial thrombotic diseases , comprising administering an effective amount of one of the compounds the dosage required to obtain such an effect is conveniently 0 . 001 to 1 . 0 mg / kg , preferably 0 . 003 to 0 . 3 mg / kg when administered by intravenous bolus ; and 0 . 001 to 0 . 5 mg / kg / h , preferably 0 . 003 to 0 . 1 mg / kg / h by intravenous infusion . the invention further relates to the use of one of the abovementioned compounds a and b , the physiologically acceptable salts thereof or the mixtures thereof for preparing a pharmaceutical composition for the treatment and prevention of the arterial thrombotic diseases mentioned hereinbefore .
the present invention relates to a method of treating and preventing arterial thrombotic diseases , comprising administering an effective amount of one of the compounds a = 1 - methyl - 2 -- oxymethyl ]- 5 -- quinoline - 8 - sulphonylamino ]- benzimidazole and b = 1 - methyl - 2 -- aminomethyl ]- 5 -- quinoline - 8 - sulphonylamino ]- benzimidazole , the physiologically acceptable salts thereof or the mixtures thereof , and the use of these compounds for preparing corresponding pharmaceutical compositions .